PER2 expression and cellular localization play a critical role in tumor aggressiveness and drug resistance in an in vitro model of hepatocellular carcinoma

Abstract

Aim: The current in vitro study investigated the role of Period 2 (PER2) in aggressiveness and the acquisition of drug resistance in hepatocellular carcinoma (HCC).

Methods: Parental PLC/PRF/5 cells, along with everolimus-resistant (EveR) and Sorafenib-resistant (SorR) cell lines, were used in this study. PER2 expression was silenced using siRNA knockdown (KD) and blocked using CRISPR/Cas9 Plasmid knockout (KO). PER2 expression levels were assessed by quantitative real-time reverse transcription polymerase chain reaction and immunofluorescence, together with markers of epithelial-mesenchymal transition, casein kinase 1ε (CK1ε), and tumor protein p53. Modulation of p53, p21, cellular myelocytomatosis oncogene, and mouse double minute 2 homolog was investigated by western blot. Mitochondrial activity was evaluated using the Seahorse System. The role of PER2 on the onset of aggressiveness was examined through assays of cell proliferation, migration, and colony formation.

Results: PLC/PRF/5 everolimus-resistant (EveR), SorR, PER2 KD, and PER2 KO cells expressed significantly lower PER2 mRNA and protein levels compared to the parental PLC/PRF/5 cells. Remarkably, in PLC/PRF/5 EveR and SorR cells, PER2 protein was entirely localized in the cytoplasm, where it colocalized with CK1ε, in contrast to the parental cells. In PLC/PRF/5 EveR, PER2 KD and PER2 KO cells, but not in SorR cells, E-cadherin was significantly decreased while vimentin and ZEB1 protein levels were significantly increased across all modified cell models. Interestingly, p53 expression was reduced in PER2 KO cells and completely absent in PLC/PRF/5 EveR and SorR cells. Consistent with these findings, the inhibitory effect of everolimus (10^-9 M) and sorafenib (5 × 10^-6 M) on cell proliferation, migration, and colony formation observed in parental PLC/PRF/5 cells were reversed in PER2 KD and KO cells, which was accompanied by upregulation of oncogenes, downregulation of tumor suppressor genes, and alterations in mitochondrial activity.

Conclusion: These results suggest that the acquisition of an aggressive phenotype is characterized by reduced PER2 expression and loss of its nuclear translocation, which, in turn, is associated with resistance to systemic therapy in hepatocellular carcinoma.

Keywords

Clock genes / Period 2 / hepatocellular carcinoma / epithelial-mesenchymal transition (EMT) / everolimus / sorafenib / drug resistance

References

[1] Shearman LP,Weaver DR.Interacting molecular loops in the mammalian circadian clock.Science2000;288:1013-9

[2] Takahashi JS,Ko CH.The genetics of mammalian circadian order and disorder: implications for physiology and disease.Nat Rev Genet2008;9:764-75 PMCID:PMC3758473

[3] Lee Y.Roles of circadian clocks in cancer pathogenesis and treatment.Exp Mol Med2021;53:1529-38 PMCID:PMC8568965

[4] Battaglin F,Pan Y.Clocking cancer: the circadian clock as a target in cancer therapy.Oncogene2021;40:3187-200 PMCID:PMC8549632

[5] Morales-Santana S,Leon J,Jimenez-Lopez JC.An overview of the polymorphisms of circadian genes associated with endocrine cancer.Front Endocrinol (Lausanne)2019;10:104 PMCID:PMC6401647

[6] Li HX.The role of circadian clock genes in tumors.Onco Targets Ther2019;12:3645-60 PMCID:PMC6526167

[7] Jiang Y,Fasae MB.The expression and function of circadian rhythm genes in hepatocellular carcinoma.Oxid Med Cell Longev2021;2021:4044606 PMCID:PMC8541861

[8] Villanueva A.Hepatocellular carcinoma. Reply.N Engl J Med2019;381

[9] Llovet JM,Heikenwalder M.Immunotherapies for hepatocellular carcinoma.Nat Rev Clin Oncol2022;19:151-72

[10] Finn RS,Ikeda M.IMbrave150 InvestigatorsAtezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.N Engl J Med2020;382:1894-905

[11] Abou-Alfa GK,Kudo M.Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.NEJM Evid2022;1:EVIDoa2100070

[12] Ducreux M,Bekaii-Saab T.The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/world congress on gastrointestinal cancer, Barcelona, 2022.ESMO Open2023;8:101567.

[13] Kinouchi K.Metabolic rivalry: circadian homeostasis and tumorigenesis.Nat Rev Cancer2020;20:645-61

[14] Mteyrek A,Guettier C,Lévi F.Clock gene Per2 as a controller of liver carcinogenesis.Oncotarget2016;7:85832-47 PMCID:PMC5349878

[15] Hassan SA,von Harten M,Korf HW.Time-dependent changes in proliferation, DNA damage and clock gene expression in hepatocellular carcinoma and healthy liver of a transgenic mouse model.Int J Cancer2021;148:226-37

[16] Chen X,Wang H,Deng X.Period2 is associated with immune cell infiltration and is a potential diagnostic and prognostic marker for hepatocellular carcinoma.Front Mol Biosci2023;10:1264553 PMCID:PMC10702766

[17] Yang SL,Jiang JX,Fang X.Hepatitis B virus X protein disrupts the balance of the expression of circadian rhythm genes in hepatocellular carcinoma.Oncol Lett2014;8:2715-20 PMCID:PMC4214404

[18] Li H,Chen H.Dysregulation of metallothionein and circadian genes in human hepatocellular carcinoma.Chronobiol Int2017;34:192-202

[19] Provvisiero DP,de Angelis C.Vitamin D reverts resistance to the mTOR inhibitor everolimus in hepatocellular carcinoma through the activation of a miR-375/oncogenes circuit.Sci Rep2019;9:11695 PMCID:PMC6690984

[20] Negri M,Simeoli C.Cortisol circadian rhythm and insulin resistance in muscle: effect of dosing and timing of hydrocortisone exposure on insulin sensitivity in synchronized muscle cells.Neuroendocrinology2021;111:1005-28

[21] Pivonello C,De Martino MC.The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma.Oncotarget2016;7:9718-31 PMCID:PMC4891079

[22] Negri M,Gentile A.Vitamin D reverts the exosome-mediated transfer of cancer resistance to the mTOR inhibitor Everolimus in hepatocellular carcinoma.Front Oncol2022;12:874091 PMCID:PMC9083073

[23] Franken NA,Stap J,van Bree C.Clonogenic assay of cells in vitro.Nat Protoc2006;1:2315-9

[24] Liberti MV.The warburg effect: how does it benefit cancer cells?.Trends Biochem Sci2016;41:211-8

[25] Pfeiffer T,Bonhoeffer S.Cooperation and competition in the evolution of ATP-producing pathways.Science2001;292:504-7

[26] Zheng J.Energy metabolism of cancer: Glycolysis versus oxidative phosphorylation (Review).Oncol Lett2012;4:1151-7 PMCID:PMC3506713

[27] Goede P, Wefers J, Brombacher EC, Schrauwen P, Kalsbeek A. Circadian rhythms in mitochondrial respiration.J Mol Endocrinol2018;60:R115-30 PMCID:PMC5854864

[28] Akashi M,Yoshino T.Control of intracellular dynamics of mammalian period proteins by casein kinase I epsilon (CKIepsilon) and CKIdelta in cultured cells.Mol Cell Biol2002;22:1693-703 PMCID:PMC135601

[29] Eide EJ,Kang H.Control of mammalian circadian rhythm by CKIepsilon-regulated proteasome-mediated PER2 degradation.Mol Cell Biol2005;25:2795-807 PMCID:PMC1061645

[30] Ladd AD,Sahin I.Mechanisms of drug resistance in HCC.Hepatology2024;79:926-40

[31] Liu H,Hai R,Luo X.The role of circadian clocks in cancer: Mechanisms and clinical implications.Genes Dis2023;10:1279-90 PMCID:PMC10310980

[32] Guo F,Chen G.Aberrant expression and subcellular localization of PER2 promote the progression of oral squamous cell carcinoma.Biomed Res Int2020;2020:8587458 PMCID:PMC7060452

[33] Rubtsova SN,Gloushankova NA.Dual role of E-cadherin in cancer cells.Tissue Barriers2022;10:2005420 PMCID:PMC9621038

[34] Burandt E,Gorbokon N.E-cadherin expression in human tumors: a tissue microarray study on 10,851 tumors.Biomark Res2021;9:44 PMCID:PMC8180156

[35] Mukherjee S,Chhabra R,Bhatti JS.Targeting mitochondria as a potential therapeutic strategy against chemoresistance in cancer.Biomed Pharmacother2023;160:114398

[36] Brand MD.Assessing mitochondrial dysfunction in cells.Biochem J2011;435:297-312 PMCID:PMC3076726

[37] An X,Liu J,Yang L.Oxidative cell death in cancer: mechanisms and therapeutic opportunities.Cell Death Dis2024;15:556 PMCID:PMC11294602

[38] Zou Z,Li H.mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges.Cell Biosci2020;10:31 PMCID:PMC7063815

[39] Martinet W,De Meyer GR.Everolimus-induced mTOR inhibition selectively depletes macrophages in atherosclerotic plaques by autophagy.Autophagy2007;3:241-4

[40] Gotoh T,Liu J,Finkielstein CV.Association of the circadian factor Period 2 to p53 influences p53’s function in DNA-damage signaling.Mol Biol Cell2015;26:359-72 PMCID:PMC4294682

[41] Menendez D,Resnick MA.The expanding universe of p53 targets.Nat Rev Cancer2009;9:724-37

[42] Zhang L,Hu M.Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression.Cancer Res2000;60:3655-61

[43] Levine AJ.The first 30 years of p53: growing ever more complex.Nat Rev Cancer2009;9:749-58 PMCID:PMC2771725

[44] Abukhdeir AM.P21 and p27: roles in carcinogenesis and drug resistance.Expert Rev Mol Med2008;10:e19 PMCID:PMC2678956

[45] Moll UM.The MDM2-p53 interaction.Mol Cancer Res2003;1:1001-8

[46] Rayburn E,He J.MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy.Curr Cancer Drug Targets2005;5:27-41

[47] Wang H. MDM2 oncogene as a novel target for human cancer therapy.Curr Pharm Des2000;6:393-416

[48] Sahin I,Navaraj A.AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killing.Cell Death Discov2020;6:57 PMCID:PMC7338458

[49] Fu L,Liu J,Lee C.The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo.Cell2002;111:41-50